君实生物-U
(688180)
| 流通市值：262.41亿 | | | 总市值：351.54亿 |
| 流通股本：7.66亿 | | | 总股本：10.27亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 726,287,839.6 | 2,498,420,333.97 | 1,805,880,133.52 | 1,168,383,949.66 |
| 营业收入 | 726,287,839.6 | 2,498,420,333.97 | 1,805,880,133.52 | 1,168,383,949.66 |
| 二、营业总成本 | 861,878,028.11 | 3,444,363,178.98 | 2,473,163,074.83 | 1,659,107,714.05 |
| 营业成本 | 146,975,372.39 | 466,504,699.5 | 349,484,894.43 | 232,973,225.29 |
| 税金及附加 | 6,137,644.64 | 23,035,017.99 | 17,010,344.94 | 12,528,558.6 |
| 销售费用 | 251,772,425.71 | 1,052,990,110.91 | 768,276,592.69 | 487,343,366.83 |
| 管理费用 | 138,640,081.25 | 494,437,195.29 | 309,903,370.97 | 195,138,037.85 |
| 研发费用 | 282,495,448.11 | 1,342,123,173.56 | 982,154,685.41 | 705,577,750.61 |
| 财务费用 | 35,857,056.01 | 65,272,981.73 | 46,333,186.39 | 25,546,774.87 |
| 其中:利息费用 | 23,987,870.26 | 64,317,116.52 | 49,879,352.25 | 34,369,768.3 |
| 其中:利息收入 | 7,392,058.78 | 31,884,720.61 | 22,419,800.04 | 13,670,651.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -13,362,009.89 | 57,210,254.39 | 58,015,785.81 | 55,513,847.65 |
| 加:投资收益 | 120,894,987.1 | -106,416,782.78 | -38,850,784.62 | -20,282,414.15 |
| 资产处置收益 | 176,910.96 | 35,259,378.72 | 5,647,379.8 | 7,583,182.57 |
| 资产减值损失(新) | -8,310,977.38 | -98,098,076.08 | -69,246,433.64 | -50,738,807.77 |
| 信用减值损失(新) | -3,199,702.43 | 3,358,644.43 | -1,388,305.03 | 2,360,666.75 |
| 其他收益 | 10,803,119.67 | 55,166,042.41 | 42,047,057.38 | 21,276,210.8 |
| 四、营业利润 | -28,587,860.48 | -999,463,383.92 | -671,058,241.61 | -475,011,078.54 |
| 加:营业外收入 | 158,927.36 | 777,285.04 | 497,714.47 | 174,923.09 |
| 减:营业外支出 | 9,413,651.59 | 24,588,243.19 | 21,832,594.27 | 10,375,434.67 |
| 五、利润总额 | -37,842,584.71 | -1,023,274,342.07 | -692,393,121.41 | -485,211,590.12 |
| 减:所得税费用 | 5,582,837.13 | -13,880,931.62 | -18,083,252.3 | -19,538,177.93 |
| 六、净利润 | -43,425,421.84 | -1,009,393,410.45 | -674,309,869.11 | -465,673,412.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -43,425,421.84 | -1,009,393,410.45 | -674,309,869.11 | -465,673,412.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -20,564,028.12 | -875,174,332.71 | -595,700,160.22 | -412,695,598.44 |
| 少数股东损益 | -22,861,393.72 | -134,219,077.74 | -78,609,708.89 | -52,977,813.75 |
| 扣除非经常损益后的净利润 | -143,609,202 | -989,649,539.24 | -669,805,624.99 | -478,428,231.35 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.87 | -0.6 | -0.42 |
| (二)稀释每股收益 | -0.02 | -0.87 | -0.6 | -0.42 |
| 八、其他综合收益 | 5,922,552.06 | -6,750,254.67 | -146,608.69 | -15,916,155.46 |
| 归属于母公司股东的其他综合收益 | 5,922,552.06 | -6,750,254.67 | -146,608.69 | -15,916,155.46 |
| 九、综合收益总额 | -37,502,869.78 | -1,016,143,665.12 | -674,456,477.8 | -481,589,567.65 |
| 归属于母公司股东的综合收益总额 | -14,641,476.06 | -881,924,587.38 | -595,846,768.91 | -428,611,753.9 |
| 归属于少数股东的综合收益总额 | -22,861,393.72 | -134,219,077.74 | -78,609,708.89 | -52,977,813.75 |
| 公告日期 | 2026-04-28 | 2026-03-14 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |